Derivation Web

source_505d40f353574065

by researka:v2 · 2026-07-31 08:34:24.349162+04:00

# Research Synthesis: Semaglutide Intervention Oral Semaglutide Effects
## Abstract

Evidence scope: A subset of the retained sources is indirect, review-level, adjacent, or mechanistic and is used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on semaglutide intervention oral semaglutide effects across the retained source corpus and high-confidence extracted claim set [bundle:11].

The evidence profile separates direct interventional hard-endpoint evidence from adjacent, review, context, and mechanistic evidence, while retaining surfaced cross-study disagreements.

Positive study-level signals are summarized in the longevity outcome class; null signals are summarized in the dosing and pharmacokinetics outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, and muscle function outcome classes. The paper therefore reports a source-directness and outcome-class map rather than a pooled effect [bundle:23].

The conclusion is that semaglutide intervention oral semaglutide effects remains a bounded evidence case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim [bundle:14].

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In abstract, interpretation remains limited to the retained endpoint-specific findings. This paragraph marks that evidence boundary and adds no result or recommendation beyond the cited corpus.

## Research Question

Within the retained source corpus for semaglutide intervention oral semaglutide effects, among type 2 diabetes patients, do findings for cardiometabolic and contextual adjacent evidence support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on semaglutide intervention oral semaglutide effects across 42 included source papers and 3212 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 23 direct clinical sources, 18 adjacent, review, or context sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

### Scope of the synthesis

This synthesis treats the topic as a structured research question
rather than as a binary endorsement. The introduction therefore frames
why the intervention is scientifically relevant, why the evidence base
must be separated by directness and outcome class, and why mechanistic
plausibility cannot substitute for clinical certainty. The public
argument is intentionally bounded: it asks what the accepted evidence
can support, what remains unresolved, and what kind of future study
would most efficiently reduce uncertainty.

## Background

The background evidence for semaglutide intervention oral semaglutide effects is heterogeneous rather than uniformly confirmatory.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic and longevity outcome classes; null signals around the cardiometabolic, dosing and pharmacokinetics outcome classes; and negative or adverse signals around the cardiometabolic outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-semaglutide_intervention_oral_semaglutide_effects-v06-DAILY-2026-07-31T04-20-54Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-31.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `semaglutide intervention oral semaglutide effects aging`
- `semaglutide intervention oral semaglutide effects older adults`
- `semaglutide intervention oral semaglutide effects randomized controlled trial`
- `semaglutide aging`
- `semaglutide older adults`
- `semaglutide randomized controlled trial`
- `intervention oral semaglutide aging`
- `intervention oral semaglutide older adults`
- `intervention oral semaglutide randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses semaglutide intervention oral semaglutide effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 173 records in the receipt-candidate union, 53 were classified as source candidates and 42 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 173 |
| Classified source candidates | 53 |
| No extractable claims | 5 |
| None-only claim binding | 3 |
| Mixed partial-or-none claim-binding candidates | 42 |
| Partial-only claim-binding candidates | 34 |
| Strict high-confidence sources | 36 |
| Admitted final sources | 42 |

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 42 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Araki 2021: Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=295 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Aroda 2019: PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=29 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Aroda 2022: A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes | direction=unclear | directness=mechanistic | C1 | outcome=Mechanism/Cardiometabolic; direction=unclear | finding=3 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Bain 2018: Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=58 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Buse 2020: Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=94 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Costa 2025: Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Davies 2017: Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=15 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Drygalski 2025: Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis. | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Gibbons 2020: Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=66 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Holdt-Caspersen 2025: Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial | direction=null | directness=protocol | D1 | outcome=Cardiometabolic; direction=null | finding=20 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Janic 2022: Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS) | direction=unclear | directness=protocol | D1 | outcome=Mechanism/Cardiometabolic; direction=unclear | finding=32 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Jena 2026: Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=140 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ji 2024: Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=476 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ji 2025: Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=54 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Kadowaki 2025: Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Kaku 2018: Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=189 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Li 2023: Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis. | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=11 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Mann 2025: Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.19; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Marx 2025: Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=80 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Mulvagh 2026: Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=89 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Nomoto 2022: Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study) | direction=unclear | directness=protocol | D1 | outcome=Cardiometabolic; direction=unclear | finding=26 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Oe 2024: Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study) | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.01; source-level statistic reported |
| Cardiometabolic | Ojinna 2026: A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=10 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Pop-Busui 2026: Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=65 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Postema 2025: Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=117 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Rosenstock 2019: Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=17 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Shamrok 2025: Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Tan 2025: Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials | direction=positive | directness=review | B1 | outcome=Cardiometabolic; direction=positive | finding=83 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Thethi 2020: Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=21 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Tilici 2025: Modulation of metabolic syndrome components by oral semaglutide in hypothyroid–T2DM patients: a retrospective analysis | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Wang 2024a: Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=420 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Wang 2024b: 7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=13 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Wannachalee 2026: Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=175 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Wharton 2025: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=7 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Yabe 2022: Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=81 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Yamada 2022: Efficacy and safety of oral semaglutide by baseline age in J apanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 J apan trials | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=66 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Zaccardi 2026: Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=73 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Zhang 2024: Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis. | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=15 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Masson 2024: Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis | direction=unclear | directness=review | B1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=46 extracted claim(s); source-level direction is the coded finding |
| Dosing and Pharmacokinetics | Kimura 2025: Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study | direction=null | directness=protocol | D1 | outcome=Dosing and Pharmacokinetics; direction=null | finding=28 extracted claim(s); source-level direction is the coded finding |
| Longevity | Effects of Oral Semaglutide 2025: Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial | direction=positive | directness=direct | A1 | outcome=Longevity; direction=positive | finding=representative statistic P = 0.0177; source-level statistic reported |
| Muscle Function | Effect of Oral Semaglutide 2026: The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=1 extracted claim(s); source-level direction is the coded finding |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim [bundle:5].

| Evidence domain | Corpus slice | Direction profile | Directness | Main limitation |
|---|---|---|---|---|
| Semaglutide Intervention Oral Semaglutide Effects / Cardiometabolic | n=38; claims=3133 | positive=5, negative=1, null=5, mixed=6, unclear=21 (n=38) | 21 direct; 6 indirect; 1 mechanistic; 3 protocol; 7 review | limited corpus depth in this outcome class |
| Semaglutide Intervention Oral Semaglutide Effects / Contextual Adjacent Evidence | n=1; claims=46 | positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1) | 1 review | single-source slice; hypothesis-generating |
| Semaglutide Intervention Oral Semaglutide Effects / Dosing and Pharmacokinetics | n=1; claims=28 | positive=0, negative=0, null=1, mixed=0, unclear=0 (n=1) | 1 protocol | single-source slice; hypothesis-generating |
| Semaglutide Intervention Oral Semaglutide Effects / Longevity | n=1; claims=4 | positive=1, negative=0, null=0, mixed=0, unclear=0 (n=1) | 1 direct | single-source slice; hypothesis-generating |
| Semaglutide Intervention Oral Semaglutide Effects / Muscle Function | n=1; claims=1 | positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1) | 1 direct | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Dosing and pharmacokinetics context: 2 sources; positive signal in 1/2 sources.
- Aging and geroscience context: 1 sources; no extracted directional signal in 1/1 sources.
- Skeletal and muscle context: 1 sources; unclear signal in 1/1 sources.

### Cardiometabolic Outcomes

The cardiometabolic evidence base for oral semaglutide is anchored by direct randomized clinical trials across glycemic, anthropometric, and cardiovascular endpoints [bundle:24].

Within-corpus tensions on cardiometabolic endpoints are prominent. The review aggregates semaglutide therapy arms across enrolled trials and contrasts them with placebo and active-control comparators, with CRP index as the primary inflammation endpoint. The cited p-value of P = 0.098 was extracted as part of the review's pooled estimate reporting, and the canonical trial identifier is reported as (none) because the synthesis is meta-analytic rather than a single registered RCT.

Mechanistically, the CRP-lowering signal aligns with broader cardiometabolic and longevity pathways attributed to GLP-1 receptor agonism, including downstream modulation of adipose-derived inflammatory mediators and improved glycemic-driven oxidative stress. The review's directness is annotated as 'review', consistent with its role as indirect/contextual evidence rather than a primary efficacy trial, and the population field is reported as N/A (mechanistic / indirect — no enrolled clinical population) within the source [bundle:7].

The protocol is framed as a disease-modifying investigation and explicitly engages the dose-exposure question, with the title signalling that safety and optimal dose are co-primary objectives of the trial. The cited source excerpts limit the available quantitative detail to the design parameters and population, with no effect estimates, p-values, or sample sizes reported in the source. Accordingly, this outcome class is represented by a single protocol-level evidence unit that anchors the dosing rationale for oral semaglutide in a neuroprotective indication rather than by mature efficacy data [bundle:13].

Within the corpus, dosing and pharmacokinetics is therefore a null-finding outcome class, in that the only contribution is a forward-looking design rather than a completed comparison. No dose-ranging head-to-head numerics are available in the source, so the within-class quantitative density is limited to the design parameters themselves [bundle:25].

The class is therefore characterized by a single design contribution rather than by competing findings. The integrating brief's flag that null findings dominate dosing pharmacokinetics is consistent with this evidence map: the corpus supplies a protocol scaffold but no completed efficacy estimate in this outcome class, and the boundary conditions for oral semaglutide dosing in non-cardiometabolic indications remain to be established by the planned trial [bundle:34].

Mulvagh 2026 [bundle:10] reports: Treatment with oral semaglutide led to a statistically significant 14% reduction in the risk of major adverse cardiovascular events (MACE) compared with placebo [exact source: https://doi.org/10.1001/jamacardio.2026.0245].

Marx 2025 [bundle:13] reports: Over a mean follow-up of 47.5±10.9 months, the risk of the primary outcome in the overall trial population was 14% lower for oral semaglutide versus placebo hazard ratio, 0.86 [exact source: https://doi.org/10.1161/CIRCULATIONAHA.125.074545].

Gibbons 2020 [bundle:17] reports: Overall, mean body weight decreased by 2.7 kg with oral semaglutide and 0.1 kg with placebo, mostly attributable to body fat mass loss [exact source: https://doi.org/10.1111/dom.14255].

Oe 2024 [bundle:7] reports: Their HbA1c and body weight significantly decreased - 13.1 ± 7.5 mmol/mol and - 3.0 ± 2.4 kg, respectively [exact source: https://doi.org/10.1186/s12902-024-01658-6].

Tan 2025 [bundle:11] reports: Four RCTs ( n = 19,663) showed semaglutide significantly reduced primary outcome risk HR 0.83 [exact source: https://doi.org/10.3389/fcvm.2025.1731127].

Tilici 2025 [bundle:14] reports: At 6 months, mean HbA1c decreased by 6.7% ( P < 0.001), BMI was reduced by 4.04% ( P < 0.001), triglycerides decreased by 6.7% ( P < 0.001), and HDL-C increased by 9% ( P = 0.002) [exact source: https://doi.org/10.25122/jml-2025-0144].

Li 2023 [bundle:28] reports: Compared with placebo, semaglutide 7 and 14 mg reduced HbA1c by 1.06% (95% CI, 0.81-1.30) and 1.10% (95% CI, 0.88-1.31), respectively [exact source: https://doi.org/10.1016/j.diabres.2023.110605].

Li 2023 [bundle:28] reports: While in comparison with other antidiabetic agents, semaglutide 7 and 14 mg reduced HbA1c by 0.26% (95% CI, 0.15-0.38) and 0.38% (95%CI, 0.31-0.45) [exact source: https://doi.org/10.1016/j.diabres.2023.110605].

Kadowaki 2025 [bundle:31] reports: More participants had 5% or greater body weight reductions with semaglutide vs placebo 107 of 127 [84.3%] vs 11 of 64 [17.2%] [exact source: https://doi.org/10.1001/jamainternmed.2025.3599].

### Longevity Outcomes

The SOUL trial evaluated oral semaglutide against cardiovascular endpoints in people with type 2 diabetes complicated by atherosclerotic cardiovascular disease and/or chronic kidney disease, and the source documents a pre-specified heart failure (HF) analysis embedded within that parent study design. The population was type 2 diabetes patients with established cardiovascular or renal comorbidity, and the analytic subset of interest comprised participants who entered the trial with prevalent HF at baseline. The endpoint framing was a time-to-event composite for HF outcomes, evaluated as a within-baseline-HF subgroup rather than as a stand-alone primary trial. The dose and duration parameters were those of the parent SOUL protocol; the source does not enumerate dose levels or follow-up window separately for the HF substudy.

Within the HF-at-baseline subgroup, oral semaglutide significantly reduced the risk of the heart failure endpoint, with the source recording P = 0.0177 against the control arm; the effect direction is positive, meaning a lower event rate on active therapy. The source does not provide a hazard ratio, odds ratio, or confidence interval in the excerpts available to the synthesizer, so no effect size is reported here in addition to the significance value. Likewise, absolute event counts and sample size for the HF-at-baseline subset are not transcribed in the source, and these quantities are therefore not introduced into the Results prose. The single available quantitative anchor is P = 0.0177 for the HF outcome reduction in the baseline-HF subset [bundle:18].

Mechanistically, the HF finding aligns with the broader cardiometabolic substrate that the GLP-1 receptor agonist class engages — improvements in glycemia, body weight, blood pressure, and renal trajectory — each of which is plausibly upstream of decompensation events in patients with established HF. The source is a clinical RCT, so the result is graded as direct human evidence rather than a mechanistic extrapolation, but the mechanistic substrate underlying this functional finding is consistent with the class effect reported across the GLP-1 literature. Within the curated corpus on oral semaglutide, this source is the principal human-RCT data point connecting the agent to a longevity-adjacent cardiovascular endpoint, and no other source in the accepted set supplies a competing longevity-class endpoint. Consequently, the HF result stands as the principal longevity-class signal in this synthesis [bundle:5].

There are no non-orthogonal within-class tensions in the longevity outcome class as enumerated in the cross-study disagreement map, so the discussion of disagreement is necessarily limited. The principal interpretive caveat is that the source is restricted to a baseline-HF subgroup analysis inside a larger cardiovascular outcomes trial, which constrains the transportability of the result to a primary HF population that did not have atherosclerotic cardiovascular disease or chronic kidney disease at entry. The source also does not adjudicate whether the HF benefit is driven by weight loss, glycemic control, blood pressure reduction, or a direct myocardial effect, so the mechanism discussion above remains a plausibility statement rather than a quantified decomposition. The longevity-class evidence is therefore best read as a single positive RCT signal awaiting corroboration from additional direct evidence [bundle:13].

### Muscle Function Outcomes

The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D is the single randomized placebo-controlled trial in the corpus whose primary endpoint class maps to muscle and bone function. The study enrolled type 2 diabetes patients and was designed to test whether oral semaglutide, a GLP-1 receptor agonist, favorably shifts the balance between bone build-up and degradation and influences skeletal strength. The trial hypothesis frames oral semaglutide as having a positive effect on remodeling balance and bone strength outcomes in this population.

Quantitatively, the source does not enumerate p-values or extract numeric effect sizes for the bone-turnover endpoint; the effect direction is recorded as unclear in the curated metadata. As a result, no within-source p-value, percentage change, or hazard ratio can be cited verbatim for the muscle function outcome class. The synthesis therefore reports this trial as a directly designed but directionally indeterminate contribution to the muscle function outcome class, with quantitative results deferred to the source publication.

Mechanistically, the rationale that oral semaglutide could influence bone turnover rests on GLP-1 receptor signaling in bone-remodeling pathways, providing biological plausibility for a skeletal effect of incretin-based therapy in type 2 diabetes patients. In a clinical RCT framework, this mechanistic premise is operationalized through remodeling-marker and bone-strength endpoints; however, the curated source records no confirmatory quantitative signal, leaving the mechanistic substrate untested by a positive within-trial readout in this corpus.

Within-corpus tensions for the muscle function class cannot be enumerated because the Effect of Oral Semaglutide 2026 [bundle:36] trial is the only source mapped to this outcome class, so there is no same-outcome non-orthogonal disagreement pair to surface. The principal limitation is therefore not inter-study contradiction but evidentiary thinness: one direct clinical RCT with an unclear effect direction, against a broader corpus whose muscle function coverage is otherwise absent.

### Contextual Adjacent Evidence Outcomes

Contextual Adjacent Evidence remains a separate Results slice for Semaglutide Intervention Oral Semaglutide Effects (n=1; claims=46; positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1); 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: [bundle:11]
- Masson 2024 [bundle:20] (Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis; 46 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B1).

Masson 2024 [bundle:20] reports: Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group SMD -0.56 [exact source: https://doi.org/10.3389/fcvm.2024.1379189].

Masson 2024 [bundle:20] reports: Effect size measures were expressed as standardised mean differences (SMDs) between CRP indices with their respective 95% confidence intervals (95% CIs) [exact source: https://doi.org/10.3389/fcvm.2024.1379189].

### Dosing and Pharmacokinetics Outcomes

Dosing and Pharmacokinetics remains a separate Results slice for Semaglutide Intervention Oral Semaglutide Effects (n=1; claims=28; positive=0, negative=0, null=1, mixed=0, unclear=0 (n=1); 1 protocol; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: [bundle:11]
- Kimura 2025 [bundle:22] (Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease; 28 extracted claim(s); receipt-level direction is the coded finding; outcome=Dosing and Pharmacokinetics; direction=null; directness=protocol; tier=D1).

## Cross-Domain Synthesis

Agreement between mechanism and clinical signal is strongest where the biological rationale and the directly observed outcome point in the same bounded direction. For semaglutide intervention oral semaglutide effects, direct sources such as Ji 2024 [bundle:1], Wang 2024a [bundle:2], Araki 2021 [bundle:3] define the human evidence perimeter, while mechanistic sources such as Aroda 2022 [bundle:34] explain why an effect could occur [exact source: https://doi.org/10.1007/s00125-024-06133-4] [exact source: https://doi.org/10.1007/s00125-024-06142-3] [exact source: https://doi.org/10.1111/dom.14536] [exact source: https://doi.org/10.1007/s11154-022-09735-8]. Convergence across those roles increases plausibility, but it does not make the roles interchangeable: a pathway-level observation cannot supply a missing patient outcome, and a clinical association cannot by itself identify the responsible mechanism.

Divergence is equally informative. Positive signals represented by Wannachalee 2026 [bundle:4], Tan 2025 [bundle:11], Aroda 2019 [bundle:40] occur alongside null signals represented by Zaccardi 2026 [bundle:15], Kimura 2025 [bundle:22], Holdt-Caspersen 2025 [bundle:25] and negative or adverse signals represented by Kadowaki 2025 [bundle:31] [exact source: https://doi.org/10.1111/dom.70701] [exact source: https://doi.org/10.3389/fcvm.2025.1731127] [exact source: https://doi.org/10.2337/dc19-0749] [exact source: https://doi.org/10.1111/dom.70770] [exact source: https://doi.org/10.1136/bmjopen-2025-112318] [exact source: https://doi.org/10.2196/64899] [exact source: https://doi.org/10.1001/jamainternmed.2025.3599]. Their outcome distribution spans the cardiometabolic and longevity outcome classes, the cardiometabolic, dosing and pharmacokinetics outcome classes, and the cardiometabolic outcome class. This pattern rejects a single global verdict. It indicates that the observed direction depends on what was measured and under which design, rather than showing that all endpoints respond consistently.

The outcome-class map makes that heterogeneity auditable: Cardiometabolic (mixed=6, negative=1, null=5, positive=5, unclear=21; direct=21, indirect=6, mechanistic=1, protocol=3, review=7; sources Ji 2024 [bundle:1], Wang 2024a [bundle:2], Araki 2021 [bundle:3]); Contextual Adjacent Evidence (unclear=1; review=1; sources Masson 2024 [bundle:20]); Dosing and Pharmacokinetics (null=1; protocol=1; sources Kimura 2025 [bundle:22]); Longevity (positive=1; direct=1; sources Effects of Oral Semaglutide 2025 [bundle:32]) [exact source: https://doi.org/10.1007/s00125-024-06133-4] [exact source: https://doi.org/10.1007/s00125-024-06142-3] [exact source: https://doi.org/10.1111/dom.14536] [exact source: https://doi.org/10.3389/fcvm.2024.1379189] [exact source: https://doi.org/10.1136/bmjopen-2025-112318] [exact source: https://doi.org/10.1093/eurheartj/ehaf784.4317]. These packets are compared without pooling unlike endpoints or allowing a large indirect packet to outweigh a smaller direct one. A source contributes to the cross-domain interpretation according to its own outcome, directness, and direction coding. Agreement therefore means concordance on a comparable question; disagreement means a real difference that must be explained, not averaged away.

Population is the first boundary on transfer. Evidence from adults with a defined disease state may not generalize to healthier adults, older people with multimorbidity, or populations with different baseline risk and concomitant treatment. Subgroup composition can change both the opportunity for benefit and the exposure to harm. A future confirmatory study should therefore state the target population before selecting endpoints and should preserve stratified results rather than treating demographic or disease-stage variation as residual noise.

Dose and schedule form a separate boundary. Findings from one formulation, titration pattern, exposure level, or treatment duration cannot be assumed to describe another. An apparent mechanism-clinical mismatch may reflect inadequate exposure, different adherence, or a comparison between therapeutic and non-equivalent regimens. The synthesis consequently keeps dose-specific evidence attached to its source context and treats cross-dose consistency as an empirical question for head-to-head or prospectively harmonized studies.

Endpoint distance is the third boundary. Biomarkers and intermediate physiological measures can support a mechanistic chain, but they are not substitutes for function, symptoms, clinical events, safety, or survival. Conversely, a null distal endpoint does not automatically refute an upstream biological effect if the study was too short or the endpoint was insensitive. The decisive test is whether a prespecified chain links the mechanism to a patient-relevant outcome within a credible follow-up window.

Time horizon and safety determine whether an initially favorable signal remains clinically meaningful. Short follow-up can capture early response while missing attenuation, compensatory effects, treatment discontinuation, or delayed harm. Longitudinal evidence must therefore be read alongside tolerability and competing-risk information. A durable interpretation would require repeated measurement, explicit attrition accounting, and enough observation to distinguish transient biological movement from sustained benefit in the target population.

Comparator choice determines what a directional result can mean. Placebo, usual care, active treatment, and add-on designs estimate different contrasts, especially when background therapy already affects the same pathway or endpoint. Baseline risk also changes the room available for improvement and the absolute relevance of harm. Cross-domain agreement should therefore be tested within comparable treatment contexts; otherwise an apparent conflict may be a difference in the question asked rather than a contradiction in the underlying evidence.

Measurement and analysis complete the boundary map. Outcome definitions, ascertainment methods, missing-data rules, multiplicity control, and blinded adjudication can alter whether the same underlying response is coded as positive, null, mixed, or unclear. A decisive replication should predefine the directional rule and clinically meaningful threshold, report uncertainty rather than significance alone, and preserve source-level results by outcome class. Those choices make later convergence interpretable instead of allowing analytic flexibility to mimic biological heterogeneity.

Causal interpretation requires the full sequence to remain intact. The intervention must precede the measured change, the proposed mediator must move as predicted, and the downstream endpoint must follow without a more credible competing explanation. Randomization strengthens that sequence but does not repair an unsuitable endpoint or an unrepresentative population. Observational and mechanistic sources can identify candidate links, while a confirmatory design must test those links together and prespecify which break would falsify the proposed explanation.

Across the retained evidence, a high-density pairwise disagreement map are treated as design information. Some disagreements may be explained by population, dose, comparator, endpoint definition, or follow-up; others may represent genuine uncertainty that the present corpus cannot resolve. The next study should be chosen to discriminate among those explanations, not merely to add another broadly related source. That means matching eligibility, intervention exposure, comparator, and outcome timing to the specific mechanism-clinical gap identified here.

The resulting interpretation is conditional rather than indecisive. Across 42 curated reference papers, the evidence base for semaglutide intervention oral semaglutide effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, longevity. Negative signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, dosing pharmacokinetics. The synthesis surfaces 481 cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The semaglutide intervention oral semaglutide effects broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest conclusion follows the direct interventional hard-endpoint evidence, with mechanistic material used to explain convergence or divergence and adjacent evidence used to define external boundaries. Claims remain limited to represented populations, tested doses, measured endpoints, and observed durations. Evidence outside those coordinates motivates further research but does not enlarge the public conclusion.

## Discussion

**Thesis:** Across 42 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: cardiometabolic, longevity. Negative signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 42 included sources. The evidence-tier distribution is: A1 (n=23), B2 (n=8), B1 (n=6), D1 (n=4), C1 (n=1). By directness, the breakdown is: direct (n=23), review (n=8), indirect (n=6), protocol (n=4), mechanistic (n=1). 25 of 42 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: type 2 diabetes patients; adults; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The most consequential limitation of this synthesis is what is absent rather than what is present, and the boundary cases deserve explicit naming because they constrain every downstream headline conclusion. The curated corpus contains 42 sources spanning the PIONEER programme, the OASIS obesity programme, SOUL cardiovascular and kidney outcomes, and several real-world cohorts, but it does not contain a long-term all-cause mortality trial of oral semaglutide in non-diabetic older adults, nor does it contain a head-to-head randomized comparison between oral semaglutide 25 mg and injectable semaglutide 2.4 mg for chronic weight management, nor does it contain a dedicated trial enrolling participants with prediabetes and frailty. Consequently, the synthesis cannot support claims about oral semaglutide reducing hard cardiovascular or mortality endpoints in primary-prevention older adults, and any such extrapolation from the diabetic secondary-prevention literature into a broad aging-related case would be unsupported by the sources present here. The general direction-of-effect signals in cardiometabolic and longevity domains that the brief highlights — positive in some studies, mixed in others, null in others — are therefore best read as conditional on the enrolled populations of the included trials, not as universally transferable estimates.

A fifth limitation is the mechanism-to-clinic gap. Several clinically relevant claims that the broader literature attributes to semaglutide are supported in this corpus only by mechanistic or preclinical sources, not by completed human RCTs. The evidence tiers are A1 (n=23), B2 (n=8), B1 (n=6), D1 (n=4), C1 (n=1), and directness is direct (n=23), review (n=8), indirect (n=6), protocol (n=4), mechanistic (n=1). Effect directions are unclear (n=23), mixed (n=6), positive (n=6), null (n=6), negative (n=1), with 25 sources carrying source-traced p-values and 481 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

Population boundary: the included sources document 3 distinct population summaries: type 2 diabetes patients; adults; older adults. Conclusions apply only within those represented populations; transfer to unrepresented ages, disease states, or baseline-risk groups remains hypothesis-generating.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 42 included sources on Semaglutide Intervention Oral Semaglutide Effects across 5 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the disagreement between Davies 2017 [bundle:42] and Rosenstock 2019 [bundle:41] on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over [exact source: https://doi.org/10.1001/jama.2017.14752] [exact source: https://doi.org/10.1001/jama.2019.2942].

Prior reviews in the corpus (Jena 2026 [bundle:5], Tan 2025 [bundle:11], Masson 2024 [bundle:20], Zhang 2024 [bundle:26], Li 2023 [bundle:28]) emphasize convergent signals on Semaglutide Intervention Oral Semaglutide Effects [exact source: https://doi.org/10.17925/EE.2026.22.1.8] [exact source: https://doi.org/10.3389/fcvm.2025.1731127] [exact source: https://doi.org/10.3389/fcvm.2024.1379189] [exact source: https://doi.org/10.1002/jcph.2483] [exact source: https://doi.org/10.1016/j.diabres.2023.110605]. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 1 | 0 | positive | replication gap |
| cardiometabolic | 21 | 17 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| muscle function | 1 | 0 | unclear | replication gap |
| contextual adjacent evidence | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap |

Matrix accounting note: Direct and indirect source counts are cumulative within each outcome class and reconcile to the Results outcome-class roster.

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: replication gap | 1 direct and 0 indirect source; direction profile: positive |
| P2 | cardiometabolic: conflict-resolution gap | 21 direct and 17 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P3 | muscle function: replication gap | 1 direct and 0 indirect source; direction profile: unclear |
| P4 | contextual adjacent evidence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for Semaglutide Intervention Oral Semaglutide Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Ji 2024 [bundle:1]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed.
- Wang 2024a [bundle:2]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed.
- Araki 2021 [bundle:3]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Kaku 2018 [bundle:38]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed.
- Mann 2025 [bundle:8]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.19.
- Buse 2020 [bundle:9]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Mulvagh 2026 [bundle:10]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed.
- Yabe 2022 [bundle:12]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Marx 2025 [bundle:13]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Gibbons 2020 [bundle:17]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Ji 2024 [bundle:1]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=476.
- Wang 2024a [bundle:2]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=420.
- Araki 2021 [bundle:3]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=295.
- Kaku 2018 [bundle:38]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=189.
- Mann 2025 [bundle:8]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=95.
- Buse 2020 [bundle:9]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=94.
- Mulvagh 2026 [bundle:10]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=89.
- Yabe 2022 [bundle:12]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=81.
- Marx 2025 [bundle:13]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=80.
- Gibbons 2020 [bundle:17]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=66.
- Yamada 2022 [bundle:16]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=66.
- Pop-Busui 2026 [bundle:18]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=65.
- Bain 2018 [bundle:39]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=58.
- Ji 2025 [bundle:19]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=54.
- Aroda 2019 [bundle:40]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=29.
- Thethi 2020 [bundle:24]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=21.
- Rosenstock 2019 [bundle:41]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=17.
- Davies 2017 [bundle:42]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=15.
- Wharton 2025 [bundle:30]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=7.
- Kadowaki 2025 [bundle:31]: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=5.
- Effects of Oral Semaglutide 2025 [bundle:32]: outcome=longevity; directness=direct; tier=A1; direction=positive; claims=4.
- Shamrok 2025 [bundle:33]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=3.
- Effect of Oral Semaglutide 2026 [bundle:36]: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=1.
- Jena 2026 [bundle:5]: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=140.
- Tan 2025 [bundle:11]: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=83.
- Masson 2024 [bundle:20]: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=46.
- Zhang 2024 [bundle:26]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=15.
- Li 2023 [bundle:28]: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=11.
- Drygalski 2025 [bundle:35]: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=2.
- Wannachalee 2026 [bundle:4]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=175.
- Postema 2025 [bundle:6]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=117.
- Oe 2024 [bundle:7]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=110.
- Tilici 2025 [bundle:14]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=77.
- Zaccardi 2026 [bundle:15]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=73.
- Wang 2024b [bundle:27]: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=13.
- Ojinna 2026 [bundle:29]: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=10.
- Costa 2025 [bundle:37]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=1.
- Aroda 2022 [bundle:34]: outcome=cardiometabolic; directness=mechanistic; tier=C1; direction=unclear; claims=3.
- Janic 2022 [bundle:21]: outcome=cardiometabolic; directness=protocol; tier=D1; direction=unclear; claims=32.
- Kimura 2025 [bundle:22]: outcome=dosing pharmacokinetics; directness=protocol; tier=D1; direction=null; claims=28.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 5 disagreement: Davies 2017 [bundle:42] vs Rosenstock 2019 [bundle:41]; Davies 2017 [bundle:42] reports negative effect on body weight; Rosenstock 2019 [bundle:41] reports positive on the same endpoint — direct conflict
- Severity 5 disagreement: Davies 2017 [bundle:42] vs Aroda 2019 [bundle:40]; Davies 2017 [bundle:42] reports negative effect on body weight; Aroda 2019 [bundle:40] reports positive on the same endpoint — direct conflict
- Severity 5 disagreement: Rosenstock 2019 [bundle:41] vs Wang 2024a [bundle:2]; Rosenstock 2019 [bundle:41] reports positive effect on body weight; Wang 2024a [bundle:2] reports negative on the same endpoint — direct conflict
- Severity 5 disagreement: Rosenstock 2019 [bundle:41] vs Kadowaki 2025 [bundle:31]; Rosenstock 2019 [bundle:41] reports positive effect on body weight; Kadowaki 2025 [bundle:31] reports negative on the same endpoint — direct conflict
- Severity 5 disagreement: Aroda 2019 [bundle:40] vs Wang 2024a [bundle:2]; Aroda 2019 [bundle:40] reports positive effect on body weight; Wang 2024a [bundle:2] reports negative on the same endpoint — direct conflict
- Severity 5 disagreement: Aroda 2019 [bundle:40] vs Kadowaki 2025 [bundle:31]; Aroda 2019 [bundle:40] reports positive effect on body weight; Kadowaki 2025 [bundle:31] reports negative on the same endpoint — direct conflict
- Severity 4 null vs negative: Davies 2017 [bundle:42] vs Thethi 2020 [bundle:24]; Davies 2017 [bundle:42] (negative on body weight) vs Thethi 2020 [bundle:24] (null on body weight) — partial conflict
- Severity 4 null vs negative: Davies 2017 [bundle:42] vs Yamada 2022 [bundle:16]; Davies 2017 [bundle:42] (negative on body weight) vs Yamada 2022 [bundle:16] (null on body weight) — partial conflict

## Conclusion

For semaglutide intervention oral semaglutide effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus maps evidence for semaglutide intervention oral semaglutide effects but does not establish a general health, lifestyle, clinical, or policy recommendation. Any application remains limited to the populations, exposures, endpoints, comparators, and follow-up represented in the retained sources. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging [bundle:37].

## References

- **Ji 2024.** _Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial._ Diabetologia, 2024. DOI: 10.1007/s00125-024-06133-4 PMID: 38985161.
- **Wang 2024a.** _Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial._ Diabetologia, 2024. DOI: 10.1007/s00125-024-06142-3 PMID: 38985162.
- **Araki 2021.** _Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials._ Diabetes, Obesity & Metabolism, 2021. DOI: 10.1111/dom.14536 PMID: 34472698.
- **Kaku 2018.** _Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial._ Diabetes, Obesity & Metabolism, 2018. DOI: 10.1111/dom.13218 PMID: 29322610.
- **Wannachalee 2026.** _Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70701 PMID: 41877352.
- **Jena 2026.** _Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence._ touchREVIEWS in Endocrinology, 2026. DOI: 10.17925/EE.2026.22.1.8 PMID: 42272996.
- **Postema 2025.** _Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network._ Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.70251 PMID: 41243611.
- **Oe 2024.** _Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)._ BMC Endocrine Disorders, 2024. DOI: 10.1186/s12902-024-01658-6 PMID: 39049060.
- **Mann 2025.** _Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial._ Diabetes Care, 2025. DOI: 10.2337/dc25-1080 PMID: 41380027.
- **Buse 2020.** _Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial._ BMJ Open Diabetes Research & Care, 2020. DOI: 10.1136/bmjdrc-2020-001649 PMID: 33318068.
- **Mulvagh 2026.** _Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes._ JAMA Cardiology, 2026. DOI: 10.1001/jamacardio.2026.0245 PMID: 41879791.
- **Tan 2025.** _Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials._ Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2025.1731127 PMID: 41472878.
- **Yabe 2022.** _Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials._ Journal of Diabetes Investigation, 2022. DOI: 10.1111/jdi.13764 PMID: 35112504.
- **Marx 2025.** _Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial._ Circulation, 2025. DOI: 10.1161/CIRCULATIONAHA.125.074545 PMID: 40156843.
- **Tilici 2025.** _Modulation of metabolic syndrome components by oral semaglutide in hypothyroid–T2DM patients: a retrospective analysis._ Journal of Medicine and Life, 2025. DOI: 10.25122/jml-2025-0144 PMID: 41635458.
- **Zaccardi 2026.** _Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70770 PMID: 41994903.
- **Gibbons 2020.** _Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes._ Diabetes, Obesity & Metabolism, 2020. DOI: 10.1111/dom.14255 PMID: 33184979.
- **Yamada 2022.** _Efficacy and safety of oral semaglutide by baseline age in J apanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 J apan trials._ Diabetes, Obesity & Metabolism, 2022. DOI: 10.1111/dom.14571 PMID: 34622548.
- **Pop-Busui 2026.** _Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes._ JAMA Internal Medicine, 2026. DOI: 10.1001/jamainternmed.2025.7774 PMID: 41627802.
- **Bain 2018.** _Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial._ Diabetes, Obesity & Metabolism, 2018. DOI: 10.1111/dom.13553 PMID: 30284349.
- **Ji 2025.** _Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials._ Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.70031 PMID: 40843773.
- **Masson 2024.** _Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis._ Frontiers in Cardiovascular Medicine, 2024. DOI: 10.3389/fcvm.2024.1379189 PMID: 39055657.
- **Janic 2022.** _Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)._ Diabetes Therapy, 2022. DOI: 10.1007/s13300-022-01226-y PMID: 35258841.
- **Aroda 2019.** _PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes._ Diabetes Care, 2019. DOI: 10.2337/dc19-0749 PMID: 31186300.
- **Kimura 2025.** _Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study._ BMJ Open, 2025. DOI: 10.1136/bmjopen-2025-112318 PMID: 41448692.
- **Nomoto 2022.** _Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)._ BMJ Open, 2022. DOI: 10.1136/bmjopen-2021-056885 PMID: 35584872.
- **Thethi 2020.** _Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme._ Diabetes, Obesity & Metabolism, 2020. DOI: 10.1111/dom.14054 PMID: 32267058.
- **Holdt-Caspersen 2025.** _Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial._ JMIR Research Protocols, 2025. DOI: 10.2196/64899 PMID: 40986866.
- **Rosenstock 2019.** _Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea._ JAMA, 2019. DOI: 10.1001/jama.2019.2942 PMID: 30903796.
- **Davies 2017.** _Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes._ JAMA, 2017. DOI: 10.1001/jama.2017.14752 PMID: 29049653.
- **Zhang 2024.** _Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis._ J Clin Pharmacol, 2024. DOI: 10.1002/jcph.2483 PMID: 38874130.
- **Wang 2024b.** _7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis._ Journal of the Endocrine Society, 2024. DOI: 10.1210/jendso/bvae163.957
- **Li 2023.** _Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis._ Diabetes Res Clin Pract, 2023. DOI: 10.1016/j.diabres.2023.110605 PMID: 36871874.
- **Ojinna 2026.** _A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity._ Cureus, 2026. DOI: 10.7759/cureus.107970 PMID: 42220771.
- **Wharton 2025.** _Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity._ N Engl J Med, 2025. DOI: 10.1056/nejmoa2500969 PMID: 40934115.
- **Kadowaki 2025.** _Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial._ JAMA Intern Med, 2025. DOI: 10.1001/jamainternmed.2025.3599 PMID: 40758358.
- **Effects of Oral Semaglutide 2025.** _Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial._ European Heart Journal, 2025. DOI: 10.1093/eurheartj/ehaf784.4317
- **Shamrok 2025.** _Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk._ Alzheimer's & Dementia, 2025. DOI: 10.1002/alz70860_102127
- **Aroda 2022.** _A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes._ Reviews in Endocrine & Metabolic Disorders, 2022. DOI: 10.1007/s11154-022-09735-8 PMID: 35838946.
- **Drygalski 2025.** _Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis._ Pol Arch Intern Med, 2025. DOI: 10.20452/pamw.17141 PMID: 41117588.
- **Costa 2025.** _Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study._ Diabetes Obes Metab, 2025. DOI: 10.1111/dom.16314 PMID: 40045764.
- **Effect of Oral Semaglutide 2026.** _The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial._ 2026. Identifier unavailable; no DOI or PMID in source metadata.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "2146e052-9c0b-41f9-883c-99f7306d892f",
  "title": "Research Synthesis: Semaglutide Intervention Oral Semaglutide Effects"
}